Mohs Lab: Tissue Processing & Frozen Section Histology
The Mohs laboratory is the backbone of Mohs micrographic surgery. Every step, from tissue accessioning through frozen section interpretation, directly determines cure rates. A single processing error can obscure residual tumor and lead to incomplete excision. This article covers the complete Mohs lab workflow: specimen handling, tissue grossing and mapping, cryomold embedding, cryostat microtomy, H&E and toluidine blue staining protocols, immunohistochemistry for melanoma and perineural invasion, and quality assurance standards. Practical troubleshooting tables address the most common staining artifacts encountered in daily practice.
By Dr. Yehonatan Kaplan (M.D., Fellow ACMS)·Published: 2026-03-13·Updated: 2026-03-15·Reviewed: 2026-03-15
Mohs laboratorytissue processingfrozen sectionH&E stainingcryostatimmunohistochemistrytoluidine bluequality assurancedebulkingtissue embedding methodshematoxylin variantsSOX10PRAMEspecialized tissue processing
Key Takeaways
- The Mohs lab workflow comprises six sequential phases: accessioning, grossing/mapping, embedding, cryostat sectioning, staining, and microscopic interpretation.
- Proper tissue inking with a minimum of two colors allows precise orientation and correlation between the Mohs map and the microscopic slide.
- Embedding technique is the single most critical variable in achieving complete peripheral and deep margin visualization on a single section.
- H&E staining depends on precise pH control — hematoxylin at pH 2.5–2.9 and eosin at pH 4.0–4.5 — with differentiation occurring in acid alcohol and graded ethanol, respectively.
- Immunohistochemistry (MART-1/Melan-A, cytokeratins) extends Mohs to melanoma and perineural invasion, where routine H&E may be insufficient.
- SOX10 and PRAME have expanded the IHC panel beyond MART-1, with SOX10 detecting desmoplastic melanoma (MART-1 negative) and PRAME distinguishing melanoma from nevi with 87–94% sensitivity.
Overview of the Mohs Laboratory
Mohs micrographic surgery achieves the highest cure rates for cutaneous malignancies because of its unique en face frozen section technique, which permits examination of 100% of the surgical margin. The laboratory is where this advantage is realized. The surgeon excises tissue in the operating room, but it is the histotechnician who transforms that tissue into a readable slide within 20–40 minutes.
The Mohs lab workflow proceeds through six sequential phases:
1. Accessioning — receiving, labeling, and documenting the specimen
2. Grossing — dividing the tissue, inking margins, and creating the Mohs map
3. Embedding — mounting tissue in OCT compound on the cryomold/chuck
4. Cryostat sectioning (microtomy) — cutting 4–8 µm frozen sections
5. Staining — H&E, toluidine blue, or immunohistochemistry
6. Microscopic interpretation — the surgeon reads the slide and maps residual tumor
Each phase has specific technical parameters that determine slide quality. Failure at any step cascades downstream: poor embedding produces incomplete sections, incomplete sections produce false-negative margins, and false negatives produce recurrent tumors.
Tissue Accessioning and Specimen Handling
Accessioning begins the moment excised tissue leaves the operative field. The specimen is placed on a pre-labeled tissue tray or saline-moistened gauze and transported to the laboratory. Speed matters: desiccation begins immediately upon excision, and dried tissue produces freeze artifact and poor staining.
The histotechnician verifies the specimen against the Mohs map, confirming the number of pieces, their orientation (12 o’clock marking, nicks, or sutures), and the layer number. Each specimen is assigned a unique identifier that tracks through the entire processing chain.
Specimen Transport
Tissue should arrive in the lab within 2–5 minutes of excision. It must remain moist — either on saline-dampened gauze or in a small amount of saline. Direct immersion in fixative (formalin) is not performed in Mohs surgery because frozen section processing requires unfixed tissue.
For multi-piece layers (common in large tumors), each piece is labeled with its position on the Mohs map. Some surgeons use color-coded tissue dyes at the time of excision; others rely on orienting marks (nicks or sutures) placed before removal.
Debulking and Layer Excision
Before the first Mohs layer is taken, most surgeons debulk the clinically apparent tumor to reduce specimen size and improve tissue processing. Debulking also provides an initial specimen for histologic assessment of high-risk features (perineural invasion, aggressive subtype) that may alter surgical planning.
Debulking Technique: Blunt vs. Sharp
Two primary debulking approaches exist:
• Blunt debulking (curette): Simple, fast, and provides tactile feedback — the curette preferentially removes friable tumor while sparing firmer normal dermis. However, curetted tissue is fragmented and not suitable for histologic margin assessment.
• Sharp debulking (scalpel/scissors): Allows en bloc removal of the debulk specimen, which can then be submitted for permanent section histologic analysis. This is preferred when the surgeon needs to assess for high-risk features such as perineural invasion, depth of invasion, or aggressive histologic subtype.
Debulking increases the initial Mohs layer size (since the layer must encompass the debulked cavity) but may decrease the total number of layers needed by removing the bulk of tumor before margin-controlled excision begins.
Taking a Layer: Margins and Bevel Angle
The first Mohs layer is excised around the debulked defect (or around the intact tumor if debulking is not performed). Standard excision parameters:
• Lateral margin: 1–3 mm beyond the clinically apparent tumor border
• Bevel angle: 20–80 degrees from the skin surface (typically 45 degrees for most sites)
The bevel angle determines the ratio of peripheral-to-deep margin visible on the en face frozen section. A shallow bevel (20–30 degrees) favors peripheral margin visualization; a steep bevel (60–80 degrees) favors deep margin visualization.
Cartilage-bearing sites (ear, nose) require special consideration: cartilage is inelastic, and the overlying skin retracts significantly during tissue processing. This retraction effectively narrows the apparent margin on the slide. Surgeons compensate by taking a wider clinical margin (2–3 mm rather than 1–2 mm) and increasing the bevel angle at cartilaginous sites.
Grossing: Tissue Division, Inking, and Mapping
Grossing is the process of preparing excised tissue for embedding. It involves three critical tasks: dividing large specimens into pieces that fit flat on the cryostat chuck, inking the surgical margins for orientation, and creating a detailed map that correlates each tissue piece to its anatomic position.
Tissue Division
The goal of Mohs surgery is to examine 100% of the surgical margin on a single horizontal section. To achieve this, the excised tissue — a saucer-shaped disc — must be flattened so that the epidermis and the deep margin lie in the same cutting plane.
Small specimens (< 2 cm) can often be processed as a single piece. Larger specimens are divided into halves, thirds, or quarters using a scalpel. Each division follows specific rules:
• Cuts are made perpendicular to the skin surface, from the epidermal edge toward the deep plane
• Relaxing incisions at the epidermal edge allow the tissue to flatten without curling
• Each piece must retain its original orientation relative to the Mohs map
The number of pieces directly affects turnaround time — more pieces require more embedding, more sections, and more staining. Efficient surgeons minimize piece count without sacrificing margin visualization.
Tissue Inking
Inking the surgical margin with tissue marking dyes serves two purposes: it identifies the true surgical margin on the microscopic slide, and it allows the surgeon to correlate a positive margin on the slide with a precise location on the Mohs map.
Standard practice uses a minimum of two colors per tissue piece. Common protocols include:
• Two-color system: one color for the 12 o’clock edge, a second color for all remaining edges
• Multi-color system: different colors for each clock position (e.g., red = 12 o’clock, blue = 3 o’clock, green = 6 o’clock, black = 9 o’clock)
Ink is applied to the epidermal edge and the deep surface using a fine brush or applicator stick. The dye must dry or be fixed with acetic acid or Bouin’s solution before embedding to prevent ink from leaching into the OCT compound during freezing.
The Mohs Map
The Mohs map is a hand-drawn diagram that records the anatomic orientation of each tissue layer. It typically includes:
• An outline of the tumor defect with anatomic landmarks (nose, eye, ear, etc.)
• The excision boundary for each layer
• Division lines showing how the tissue was cut into pieces
• Ink color assignments for each edge
• Hash marks or tick marks at each division point for precise re-orientation
After slide interpretation, the surgeon marks residual tumor directly onto the map, which then guides the next excision layer. Accuracy of the map determines the precision of the re-excision — an error in mapping translates directly into unnecessary tissue removal or missed tumor.
Embedding: OCT Compound and Cryomold Technique
Embedding is the most technically demanding step in Mohs tissue processing. The tissue must be positioned so that a single horizontal cut through the block captures the entire peripheral and deep margin on one section. Poor embedding is the most common cause of false-negative Mohs sections.
Optimal Cutting Temperature (OCT) compound is a water-soluble glycol and resin mixture that provides structural support to the tissue during cryostat sectioning. The tissue is placed epidermis-down on a thin layer of OCT in a cryomold or directly on the cryostat chuck. Additional OCT is added to cover the specimen completely.
The embedding technique varies by tissue type:
• Standard flat embedding: used for most skin specimens. Tissue lies flat, epidermis-down, on the chuck surface.
• Double-embedding (Miami technique): for thick specimens. A thin layer of OCT is frozen first, creating a flat platform. The tissue is then placed epidermis-down on this frozen base and covered with more OCT.
• Vertical embedding: rarely used in Mohs. Tissue is oriented vertically to produce a cross-section (bread-loaf) view rather than the en face view.
Freezing Parameters
After embedding, the tissue block must freeze completely before sectioning. Two methods are standard:
Cryostat chamber freezing: the chuck is placed on the cryostat stage or quick-freeze bar at -25 to -30°C. Freezing takes 90–240 seconds depending on tissue thickness. This is the traditional approach used in most Mohs labs.
Flash freezing (histobath): the chuck is briefly immersed in a cold isopentane bath at -56 to -62°C. Freezing takes only 15–40 seconds. Flash freezing produces smaller ice crystals, reducing freeze artifact and improving tissue morphology. Erickson et al. (2011) demonstrated that histotechnicians found flash-frozen tissue easier to section, and surgeons preferred the histologic quality in 65–85% of paired comparisons.
Embedding Methods
Multiple embedding techniques have been described, each with specific advantages depending on tissue characteristics and laboratory workflow:
• Heat sink (heat extractor) method: The tissue is placed epidermis-down on a room-temperature metal heat sink, which rapidly freezes the contact surface while OCT is applied over the specimen. Simple and fast, but time-sensitive — delayed OCT application results in incomplete embedding.
• Glass slide method: A glass slide is placed on top of the tissue in the cryomold to compress the specimen flat during freezing. This allows direct visualization of tissue positioning, reduces air bubbles trapped between tissue and OCT, and produces consistently flat blocks.
• Miami Special (modified sponge forceps): A sponge forceps is modified to serve as both a tissue flattening device and a chuck holder. This technique standardizes the compression applied during embedding and is particularly useful for multi-piece specimens.
• Floating tissue method: The tissue is floated epidermis-down on a thin layer of liquid OCT in the cryomold. Surface tension keeps the tissue flat as the OCT freezes from the bottom up. Best suited for thin, pliable specimens.
• Reverse heat extractor method: The tissue is placed epidermis-up on frozen OCT, then flipped onto the chuck. This approach allows the histotechnician to confirm epidermal flatness before committing to the final orientation.
• Whole-mount embedding: Used for large specimens that exceed standard chuck dimensions. The tissue is embedded on oversized chucks or custom platforms, enabling en face sectioning of specimens up to 4–5 cm in diameter without division into multiple pieces. Reduces piece count and processing time for large tumors.
Cryostat Sectioning (Microtomy)
The cryostat is a refrigerated microtome housed in a chamber maintained at -20 to -25°C. The frozen tissue block is mounted on the chuck, and thin sections (4–8 µm) are cut in the horizontal (en face) plane.
The first sections off the block are the most critical — they represent the true surgical margin. The histotechnician must cut through the tissue until a complete section appears that includes the full peripheral epidermis and the entire deep margin. Sections taken before this point show incomplete margins and are diagnostically useless.
Once a full-face section is obtained, it is picked up on a glass slide by touching the warm slide to the frozen section (the tissue adheres by electrostatic attraction). The slide is then air-dried briefly and proceeds to staining.
Sectioning Parameters
Standard parameters for Mohs frozen sections include:
• Section thickness: 4–8 µm (typically 5–6 µm for routine use)
• Chamber temperature: -20 to -25°C
• Block temperature: -15 to -20°C (slightly warmer than chamber for optimal cutting)
• Blade angle: 5–15 degrees (varies by tissue type)
• Anti-roll plate: positioned to prevent section curling during cutting
Fatty tissue requires colder temperatures (-25 to -30°C) because adipose tissue freezes at a lower temperature than dermis and epidermis. Cartilaginous tissue (ear, nose) cuts best at -18 to -22°C.
| Tissue Type | Chamber Temp (°C) | Block Temp (°C) | Section Thickness (µm) | Special Considerations |
|---|---|---|---|---|
| Standard skin (face) | -20 to -22 | -15 to -18 | 5–6 | Most common; routine parameters work well |
| Fatty tissue (scalp, trunk) | -25 to -30 | -20 to -25 | 6–8 | Requires colder temps to prevent tearing; flash-freeze recommended |
| Cartilage (ear, nose) | -18 to -22 | -15 to -18 | 6–8 | Hard tissue; use sharp blade; may need slower cutting speed |
| Thin skin (eyelid) | -20 to -22 | -15 to -18 | 4–5 | Delicate tissue; handle with extreme care during pickup |
| Mucosal tissue (lip, genitalia) | -20 to -25 | -18 to -22 | 5–7 | Higher water content; freezes faster |
Specialized Tissue Techniques by Region
Certain anatomic sites require modified cryostat parameters and handling techniques to achieve diagnostic-quality frozen sections. The following table summarizes site-specific processing considerations.
| Region | Processing Considerations |
|---|---|
| Eyelid | Thin tissue; cut at 4–5 µm; extremely delicate handling during pickup to avoid tearing or folding |
| Ear | Cartilage may shatter if too cold; cut at -15 to -20°C; acetone fixation (4 min acetone, 4 min air dry) improves section quality |
| Nose | Thick tissue with cartilage; relaxing incisions essential for flattening; multiple pieces common for large specimens |
| Lip | Mucosal tissue best cut warmer (-15 to -20°C) and thinner (<8 µm) to reduce freeze artifact |
| Nail unit | Complex 3D anatomy; requires careful orientation of nail plate and matrix; consider separating nail plate from soft tissue before embedding |
| Genitourinary | Mucosal tissue with higher water content; use warmer cutting temperature (-15 to -20°C); freezes rapidly |
Hematoxylin and Eosin (H&E) Staining
H&E is the cornerstone stain for Mohs frozen sections. Hematoxylin stains nuclei blue-purple by binding to negatively charged DNA and RNA through an aluminum-hematein lake complex. Eosin stains cytoplasm and extracellular matrix in shades of pink-to-red by binding to positively charged amino acid residues in proteins. The combination produces the contrast needed to distinguish tumor cells from normal tissue.
Chemistry of the H&E Stain
Hematoxylin itself is colorless. It must be oxidized to hematein to become an active dye. Oxidation occurs naturally (ripening over weeks) or chemically (using sodium iodate or mercuric oxide as oxidizing agents). The hematein molecule then forms a coordination complex with aluminum ions (the mordant) to produce the aluminum-hematein lake — the actual staining entity. This positively charged complex binds to negatively charged phosphate groups in DNA and carboxyl groups in nuclear histones.
Differentiation with acid alcohol (0.5–1% HCl in 70% ethanol) selectively removes excess hematoxylin from non-nuclear structures. Bluing in a mildly alkaline solution (ammonia water, lithium carbonate, or Scott’s tap water substitute at pH 7–8) converts the initial red-purple hematoxylin-tissue complex to the final blue-purple color by shifting the chromophore’s absorption spectrum.
Eosin Y is an acidic (anionic) xanthene dye that binds to positively charged amino acid side chains in cytoplasmic and extracellular proteins. At optimal pH (4.0–4.5), eosin produces three distinct shades: deep red for erythrocytes and muscle, pink for cytoplasm, and pale pink for collagen and extracellular matrix. Differentiation in graded alcohols (70% and 95% ethanol) selectively removes eosin from less-avid binding sites, creating the multi-tonal effect.
Common hematoxylin formulations used in Mohs labs include Gill’s (I, II, or III, differing in hematoxylin concentration), Harris (stronger, with mercuric oxide oxidizer), and Mayer’s (progressive stain without differentiation). Most Mohs labs use Gill’s II or Harris hematoxylin with a regressive staining technique (overstain, then differentiate).
Standard H&E Staining Protocol for Frozen Sections
A typical Mohs H&E protocol takes 3–7 minutes from slide to coverslip. The exact timing varies between labs, but the sequence is universal:
1. Fixation: acetone or 10% formalin, 10–30 seconds
2. Rinse: running tap water, 15–30 seconds
3. Hematoxylin: 1–3 minutes (depending on formulation strength)
4. Rinse: running tap water, 15–30 seconds (removes excess hematoxylin)
5. Differentiation: acid alcohol (0.5% HCl in 70% ethanol), 2–5 dips
6. Rinse: running tap water, 15–30 seconds
7. Bluing: Scott’s tap water substitute or ammonia water, 30–60 seconds
8. Rinse: running tap water, 15–30 seconds
9. Eosin: 30–60 seconds
10. Dehydration: graded alcohols (70%, 95%, 100%), 10–15 seconds each
11. Clearing: xylene or xylene substitute, 30–60 seconds
12. Coverslipping: permanent mounting medium
The water rinse between bluing and eosin is critical. Carryover of the alkaline bluing reagent raises eosin pH above 4.5, producing pale, washed-out cytoplasmic staining. Thorough rinsing prevents this.
Hematoxylin Formulation Variants
The choice of hematoxylin formulation affects staining time, nuclear detail, and susceptibility to precipitate formation. Each formulation has distinct handling characteristics relevant to the Mohs frozen section workflow.
| Formulation | Type | Staining Time | Key Characteristics |
|---|---|---|---|
| Harris (with acetic acid) | Progressive | 1 min | Prone to precipitate; sharp nuclear detail; acetic acid suppresses background staining |
| Harris (without acetic acid) | Regressive | 10–15 min | Prone to precipitate; strong staining; requires acid alcohol differentiation |
| Mayer’s | Progressive | 15 min | Hard to overstain; slow but forgiving; minimal precipitate |
| Gill’s II/III | Progressive | 5 min | Ethylene glycol solvent prevents precipitate; stains goblet cells well; most popular in Mohs labs |
| Eosin Y | Counterstain | ≤30 sec | Standard cytoplasmic stain; pH 4.0–4.5 optimal |
| Eosin-phloxine B | Counterstain | 1–3 min | More vivid pinks; enhanced differentiation between collagen, muscle, and erythrocytes |
H&E Staining Troubleshooting
Staining problems are the most frequent quality issue in the Mohs laboratory. Systematic troubleshooting requires matching the observed artifact to its cause and applying the appropriate correction. The following table summarizes the most common H&E staining problems encountered in Mohs frozen section processing.
| Problem | Common Causes | Solutions |
|---|---|---|
| Smudgy nuclei / no chromatin detail | Incomplete fixation; residual water from dehydration; excessive heat during slide drying | Extend fixation time; verify dehydration protocol; reduce drying temperature; drain slides vertically before drying |
| Three eosin shades not visible | Inadequate fixation; poor eosin differentiation; eosin pH > 4.5; alkaline carryover from bluing step | Verify fixation; increase time in 70% alcohol (eosin differentiation); check eosin pH (target 4.0–4.5); rinse thoroughly after bluing |
| Poor nuclear–cytoplasmic contrast | Nuclear stain too dark or too pale relative to eosin; imbalance in staining times | Adjust hematoxylin time or differentiation time; check hematoxylin pH (target 2.5–2.9); adjust eosin concentration or staining time |
| Eosin too dark (loss of collagen/muscle differentiation) | Excessive eosin time; inadequate alcohol differentiation; aqueous vs. alcohol-based eosin mismatch; phloxine concentration too high | Decrease eosin time; increase time in 70–95% dehydrating alcohols; switch to alcohol-based eosin; reduce phloxine concentration |
| Eosin too light | Exhausted eosin solution; eosin pH > 4.5; low dye concentration; excessive differentiation in alcohols; bluing reagent carryover | Replace with fresh eosin; adjust pH with acetic acid; increase eosin concentration; decrease time in dehydrating alcohols; rinse thoroughly after bluing |
| Nuclear stain too dark | Hematoxylin too concentrated (e.g., Gill’s III vs. II); excessive staining time; inadequate differentiation | Switch to weaker formulation; decrease hematoxylin time; increase acid alcohol differentiation time |
| Nuclear stain too light | Exhausted/expired hematoxylin; incorrect pH; carryover dilution from water rinse; over-differentiation; thin sections | Replace with fresh hematoxylin; check pH (2.4–2.9); ensure neutral rinse water pH; decrease acid alcohol time; recut thicker sections |
| Uneven staining across section | Variable section thickness (chattering); solution levels below tissue; acid alcohol/bluing trapped between slides | Recut uniform section; ensure solution volumes cover all tissue; verify water wash levels exceed reagent levels |
| Red-brown nuclei (not blue-purple) | Insufficient bluing; hematoxylin over-oxidized (breaking down) | Increase bluing time; verify bluing pH ≥ 7; replace deteriorated hematoxylin |
| Dark precipitate on section | Deteriorated hematoxylin; metallic sheen (oxidized hematein) transferred to slide | Replace with fresh hematoxylin; filter solution if metallic sheen appears; store per manufacturer guidelines |
| Hazy appearance / eosin bleed | Water contamination of dehydrating alcohols or clearing solutions; inadequate dehydration after eosin | Implement routine alcohol/xylene change schedule; use minimum 3 changes of anhydrous alcohol; increase dehydration time |
| Mounting artifact (air bubbles, media on coverslip) | Mounting media too thin; air bubbles trapped during coverslipping; tissue drying before coverslip applied | Recoverslip with fresh xylene exposure; ensure adequate mounting media volume; avoid shaking mounting media container; coverslip promptly |
Toluidine Blue Staining
Toluidine blue (TB) is a metachromatic thiazine dye that stains nuclei and acid mucopolysaccharides deep blue-violet. In Mohs surgery, TB provides several advantages over H&E for detecting BCC: it stains the stromal mucin surrounding BCC nests a distinctive metachromatic purple, creating high contrast between tumor and surrounding dermis. This metachromatic property is especially useful for identifying small nests of infiltrative or morpheaform BCC that may be subtle on H&E.
Tehrani et al. (2013) demonstrated that adding TB to H&E increased a trainee’s BCC detection sensitivity from 96.3% to 99.7%, supporting the dual-stain approach during fellowship training. Styperek et al. (2016) showed that TB and H&E are statistically equivalent for SCC detection (94–96% concordance), confirming that TB can serve as a reliable primary stain for SCC as well.
Rapid Toluidine Blue Protocol
TB staining is faster than H&E — a complete protocol takes under 2.5 minutes. Todd et al. (2005) demonstrated that alkalinizing the TB solution with sodium borate reduces staining time without compromising quality.
A standard rapid TB protocol:
1. Fixation: acetone, 10 seconds
2. Rinse: tap water, 10 seconds
3. Toluidine blue (1% aqueous with 1% sodium borate): 30–60 seconds
4. Rinse: tap water, 15 seconds
5. Dehydration: 95% alcohol, 10 seconds; 100% alcohol, 10 seconds
6. Clearing: xylene, 15 seconds
7. Coverslip
Total time: approximately 2 minutes.
Immunohistochemistry in Mohs Surgery
Standard H&E staining is sufficient for most BCCs and SCCs. However, several clinical scenarios require immunohistochemical (IHC) stains to identify tumor cells that are morphologically ambiguous on frozen section:
• Melanoma in situ and invasive melanoma: melanocytes at the surgical margin are difficult to distinguish from background melanocytic hyperplasia on H&E frozen sections
• Perineural invasion: small nerve involvement by SCC or other tumors may be confirmed with nerve and tumor markers
• Desmoplastic or sclerosing tumors: bland spindle cells in a fibrous stroma can be indistinguishable from scar tissue on H&E
• Dermatofibrosarcoma protuberans (DFSP): CD34 positivity helps define tumor extent in the subcutis
IHC for Melanoma: MART-1/Melan-A and HMB-45
Mohs surgery for melanoma requires immunostaining because frozen section H&E alone cannot reliably distinguish atypical melanocytes from benign junctional melanocytes at the margin.
MART-1 (Melan-A) is the most widely used marker. It stains melanocyte cytoplasm brown, producing crisp contrast against the blue-purple hematoxylin counterstain. MART-1 labels both benign and malignant melanocytes, so interpretation depends on melanocyte density, distribution, and architectural pattern rather than simple presence or absence of staining.
HMB-45 is more specific for melanoma (it does not stain resting benign melanocytes in most cases) but has lower sensitivity. Menaker et al. (2001) found HMB-45 consistent with permanent sections in 100% of cases when a rapid staining protocol was used.
Modern rapid IHC protocols complete staining in 19–30 minutes, making same-day Mohs for melanoma feasible. These protocols use concentrated primary antibodies, polymer-based detection systems, and shortened incubation times.
Cytokeratin Staining for BCC and SCC
Cytokeratin markers (AE1/AE3, MNF 116, CK5/6) highlight epithelial tumor cells by staining intracytoplasmic keratin filaments. These markers are most useful when:
• Small BCC nests are obscured by dense inflammation
• Morpheaform/infiltrative BCC shows single-cell or thin-strand invasion that mimics fibroblasts
• Perineural SCC must be confirmed around nerve bundles
Smeets et al. (2003) found that MNF 116 cytokeratin staining detected residual BCC in 0.7% of slides judged negative on H&E alone — representing nearly 2% of treated patients. While this rate is low enough that routine cytokeratin use is not standard, adjunctive staining is warranted in selected cases of aggressive-growth BCC with ill-defined clinical borders.
Comprehensive IHC Marker Panel
The range of IHC markers used in Mohs surgery has expanded significantly beyond MART-1 and basic cytokeratins. The following table summarizes the markers most relevant to Mohs frozen section practice, including newer additions such as SOX10 and PRAME that have improved melanoma margin assessment.
| Marker | Target/Type | Primary Use in Mohs | Key Pitfalls |
|---|---|---|---|
| MART-1 (Melan-A) | Cytoplasmic melanocyte marker | Melanoma margin assessment; labels both benign and malignant melanocytes | Negative in desmoplastic melanoma; interpretation requires melanocyte density comparison |
| SOX10 | Nuclear, neural crest transcription factor | Melanoma detection, especially desmoplastic melanoma (MART-1 negative) | False positive staining in scar tissue and perineural Schwann cells |
| PRAME | Nuclear | Distinguishing melanoma from nevi (87–94% sensitivity); positive in melanoma, generally negative in nevi | Generally negative in benign nevi; limited data on frozen section protocols |
| HMB-45 | Melanosome-associated glycoprotein | Melanoma confirmation; more specific than MART-1 for malignant melanocytes | Stains junctional melanocytes in normal skin; lower sensitivity than MART-1 |
| S100 | Cytoplasmic + nuclear | Pan-melanocyte marker; nerve sheath evaluation | Also positive in Schwann cells, Langerhans cells, adipocytes, and chondrocytes — low specificity |
| CK5/6 | High-molecular-weight keratin | SCC and BCC identification in tissue with dense inflammation | Not specific to malignancy; stains normal basal keratinocytes and adnexal epithelium |
| AE1/AE3 (pancytokeratin) | Pan-epithelial keratin cocktail | SCC, BCC, microcystic adnexal carcinoma (MAC), sebaceous carcinoma | Very broad reactivity; must be interpreted in morphologic context |
| CK7 | Low-molecular-weight keratin | Extramammary Paget disease (EMPD); sebaceous carcinoma | Also positive in normal eccrine and apocrine sweat glands |
| CK20 | Low-molecular-weight keratin | Merkel cell carcinoma (MCC) — characteristic perinuclear dot pattern | Also expressed in some GI tumors; negative in approximately 10% of MCC |
| Ber-EP4 | Cytoplasmic epithelial adhesion molecule | BCC identification; distinguishes BCC from SCC and trichoepithelioma | Not reliable for basosquamous carcinoma; variable staining in morpheaform BCC |
| CEA | Cytoplasmic carcinoembryonic antigen | Highlights ductal structures in MAC; positive in EMPD | Variable sensitivity; should be used as part of a panel rather than alone |
| EMA | Epithelial membrane antigen | EMPD, sebaceous carcinoma, MAC | Not specific alone; positive in many normal and neoplastic epithelial tissues |
| CD34 | Membrane glycoprotein | DFSP margin assessment | Decreased or lost in fibrosarcomatous transformation of DFSP; also positive in normal dermal dendrocytes |
| CD31 | Endothelial cell marker | Angiosarcoma identification and margin assessment | Most sensitive and specific endothelial marker; superior to CD34 for vascular tumors |
| p63 | Nuclear epithelial transcription factor | Distinguishes primary adnexal carcinoma from metastatic adenocarcinoma | Not specific to malignancy; positive in normal basal and myoepithelial cells |
Quality Assurance for IHC
The U.S. FDA classifies IHC reagents into three categories that determine the level of laboratory validation required:
• In Vitro Diagnostic (IVD): FDA-cleared for specific diagnostic use; requires performance verification, not full validation
• Analyte-Specific Reagent (ASR): laboratory develops the test using purchased antibodies; requires full validation with positive and negative controls
• Research Use Only (RUO): not approved for clinical diagnosis; requires comprehensive validation before clinical application
CLIA regulations mandate that Mohs labs performing IHC maintain documentation of antibody validation, lot-to-lot verification, positive and negative controls run with each staining batch, and annual proficiency testing. Positive controls should include tissue with known antigen expression; negative controls omit the primary antibody or use an isotype-matched irrelevant antibody.
Quality Assurance and Laboratory Standards
Mohs laboratories operate under CLIA (Clinical Laboratory Improvement Amendments) regulations in the United States. Quality assurance encompasses every phase of the laboratory workflow — from specimen handling through result reporting.
Daily Quality Checks
A structured daily QA checklist should include:
• Cryostat temperature verification (chamber and stage temperatures recorded)
• Hematoxylin pH check (target 2.5–2.9)
• Eosin pH check (target 4.0–4.5)
• Blade condition assessment (replace if chattering or chipping observed)
• Control slide review: process a control tissue section through the full staining protocol at the start of each session
• Reagent expiration date check
• Staining log entry with date, technician initials, and any deviations noted
| QA Parameter | Target Value | Check Frequency | Action if Out of Range |
|---|---|---|---|
| Cryostat chamber temp | -20 to -25°C | Daily (morning) | Recalibrate; do not cut until in range |
| Hematoxylin pH | 2.5–2.9 | Daily | Adjust with acid per original formulation or replace |
| Eosin pH | 4.0–4.5 | Daily | Adjust with acetic acid or replace with fresh solution |
| Blade condition | No visible nicks | Every 5–10 blocks | Replace blade; inspect anti-roll plate |
| Control slide quality | Crisp nuclei, 3-tone eosin | Daily (first slide) | Troubleshoot per H&E table before processing patient tissue |
| Reagent expiration | Within date | Weekly | Discard expired reagents; reorder |
Reagent Management
Staining reagents degrade with use, exposure to air, and time. A reagent rotation schedule prevents gradual quality deterioration that may go unnoticed day-to-day but produces cumulative staining problems.
Hematoxylin solutions are particularly prone to over-oxidation. Once all hematein is converted beyond the active stage, the solution loses staining capacity. Harris hematoxylin should be filtered when a metallic sheen appears on the surface. All hematoxylin formulations should be stored in tightly sealed dark containers at room temperature.
Eosin solutions are more stable but lose staining intensity as the dye concentration decreases with use. Monitoring pH is the most reliable indicator of eosin quality — a rise above pH 4.5 signals the need for replacement or pH adjustment with acetic acid.
Alcohol and xylene solutions should be rotated on a fixed schedule. Water contamination of dehydrating alcohols is the most common cause of hazy, poorly cleared sections.
Frozen Section Interpretation
The Mohs surgeon examines the stained frozen section under the microscope, systematically scanning the entire peripheral and deep margin. The slide is oriented using the ink colors to match each section edge to its corresponding position on the Mohs map.
Interpretation follows a standard sequence:
1. Low-power scan (4×): identify tissue orientation, ink colors, and overall architecture; screen for obvious tumor nests
2. Medium-power review (10×): examine the surgical margin systematically from one ink color through the entire periphery and deep margin; identify suspicious areas
3. High-power confirmation (20–40×): evaluate suspicious areas for definitive tumor identification; assess perineural and lymphovascular invasion if relevant
When residual tumor is identified, the surgeon marks its location on the Mohs map using the ink-color orientation. The next excision layer targets only the area with positive margins — this is the tissue-sparing principle that distinguishes Mohs from standard excision.
Common Frozen Section Artifacts
Frozen sections inevitably contain artifacts that must be distinguished from true pathology. Recognition of these artifacts is a core skill for the Mohs surgeon.
| Artifact | Appearance | Cause | Prevention |
|---|---|---|---|
| Freeze artifact | Vacuolated cytoplasm, retraction around cells | Ice crystal formation during slow freezing | Flash-freeze in isopentane; avoid tissue desiccation before embedding |
| Chattering | Parallel bands of thick/thin tissue | Dull blade, improper blade angle, or vibration | Replace blade; adjust angle; ensure anti-roll plate is properly positioned |
| Tissue folding | Overlapping tissue layers creating apparent hypercellularity | Section folded during pickup onto slide | Use gentle slide-to-section contact; flatten with fine brush |
| Ink artifact | Dark pigment obscuring tissue detail | Ink leaching from poorly dried tissue dye into OCT | Allow ink to dry completely; fix with acetic acid before embedding |
| Cautery artifact | Eosinophilic, elongated, homogenized cells at margin | Electrosurgical damage during excision | Distinguish from viable tumor; may require re-excision beyond cauterized zone |
Frequently Asked Questions
Related Articles
References
- [1]Chen ELA, Srivastava D, Nijhawan RI. Mohs Micrographic Surgery: Development, Technique, and Applications in Cutaneous Malignancies. Semin Plast Surg. 2018. doi:10.1055/s-0038-1642057 PMID: 29765269
- [2]Larson K, Ho HH, Anumolu PL, Chen TM. Hematoxylin and eosin tissue stain in Mohs micrographic surgery: a review. Dermatol Surg. 2011. doi:10.1111/j.1524-4725.2011.02051.x PMID: 21635628
- [3]Erickson QL, Clark T, Larson K, Minsue Chen T. Flash freezing of Mohs micrographic surgery tissue can minimize freeze artifact and speed slide preparation. Dermatol Surg. 2011. doi:10.1111/j.1524-4725.2011.01926.x PMID: 21481069
- [4]Flint N, Friedman P, Frigerio A, Tinklepaugh A. Incomplete staining artifact: a confounding frozen section pathology artifact encountered during Mohs micrographic surgery. J Drugs Dermatol. 2022. doi:10.36849/JDD.6722 PMID: 35533040
- [5]Tehrani H, May K, Morris A, Motley R. Does the dual use of toluidine blue and hematoxylin and eosin staining improve basal cell carcinoma detection by Mohs surgery trainees?. Dermatol Surg. 2013. doi:10.1111/dsu.12180 PMID: 23465179
- [6]Styperek AR, Goldberg LH, Goldschmidt LE, Kimyai-Asadi A. Toluidine blue and hematoxylin and eosin stains are comparable in evaluating squamous cell carcinoma during Mohs. Dermatol Surg. 2016. doi:10.1097/DSS.0000000000000872 PMID: 27662051
- [7]Todd MM, Lee JW, Marks VJ. Rapid toluidine blue stain for Mohs micrographic surgery. Dermatol Surg. 2005. doi:10.1111/j.1524-4725.2005.31053 PMID: 15762224
- [8]Chen CL, Wilson S, Afzalneia R, Chen CJ. Topical aluminum chloride and Monsel's solution block toluidine blue staining in Mohs frozen sections: mechanism and solution. Dermatol Surg. 2019. doi:10.1097/DSS.0000000000001761 PMID: 30640770
- [9]Menaker GM, Chiang JK, Tabila B, Moy RL. Rapid HMB-45 staining in Mohs micrographic surgery for melanoma in situ and invasive melanoma. J Am Acad Dermatol. 2001. doi:10.1067/mjd.2001.111634 PMID: 11312433
- [10]Smeets NW, Stavast-Kooy AJ, Krekels GA, Daemen MJ, Neumann HA. Adjuvant cytokeratin staining in Mohs micrographic surgery for basal cell carcinoma. Dermatol Surg. 2003. doi:10.1046/j.1524-4725.2003.29089.x PMID: 12656816
- [11]Surprenant D, Reserva J, Krol C, Alam M. Quantitative and qualitative comparison of two hematoxylin and eosin staining protocols for Mohs micrographic surgery: a pilot study. Dermatol Surg. 2021. doi:10.1097/DSS.0000000000003199 PMID: 34699441
- [12]McKay C, Nehal KS. Laboratory Manual for Mohs Micrographic Surgery. Springer. 2024. doi:10.1007/978-3-031-44332-0
- [13]Zitelli JA, Moy RL, Abell E. Mohs Micrographic Surgery: Principles and Practice. Elsevier. 2015.
- [14]Aslam A, Aasi SZ. Frozen-Section Tissue Processing in Mohs Surgery. Dermatol Surg. 2019. doi:10.1097/DSS.0000000000002260 PMID: 31764292
- [15]Thornton SL, Beck B. Setting up the Mohs surgery laboratory. Dermatol Clin. 2011. doi:10.1016/j.det.2011.01.007 PMID: 21421157
- [16]Miller LJ, Argenyi ZB, Whitaker DC. The preparation of frozen sections for micrographic surgery. A review of current methodology. J Dermatol Surg Oncol. 1993. doi:10.1111/j.1524-4725.1993.tb00994.x PMID: 7504004
- [17]Kinas CG, Carroll BT. General Guidelines for Quality Assurance of Immunohistochemistry in a Mohs Lab. Dermatol Surg. 2017. doi:10.1097/DSS.0000000000001033 PMID: 28359076
- [18]Sroa N, Campbell S, Ravitskiy L. Immunohistochemistry in mohs micrographic surgery: a review of the literature. J Clin Aesthet Dermatol. 2009. PMID: 20729969
- [19]Contestable JJ, Lim GFS, Willenbrink T, Zitelli JA, Brodland DG. Mohs for Melanoma: A Review of MART-1 Frozen Section Interpretation. Dermatol Surg. 2024. doi:10.1097/DSS.0000000000004312 PMID: 38975654
- [20]Chen TM, Wanitphakdeedecha R, Whittemore DE, Nguyen TH. Laboratory assistive personnel in Mohs micrographic surgery: a survey of training and laboratory practice. Dermatol Surg. 2009. doi:10.1111/j.1524-4725.2009.01287.x PMID: 19660026
- [21]Miller LJ, Clark GB. Quality improvement in the cutaneous micrographic surgery laboratory. Clin Lab Manage Rev. 1994. PMID: 10138952
- [22]LeBoeuf M, Bieber K, Cooper S, Isenor A. Quantitative Analysis of Frozen Section Histology in Mohs Micrographic Surgery. Dermatol Surg. 2020. doi:10.1097/DSS.0000000000002231 PMID: 31688237
- [23]Long T, Dunn A, Hill D, Goldberg LH, Akin R. The Role of Toluidine Blue in Mohs Micrographic Surgery: A Systematic Review. Cutis. 2023. doi:10.12788/cutis.0915 PMID: 38290073
- [24]Davis MS, Desai RM, Baird DB, Stetson CL. Advisory on delayed fading caused by the use of a xylene substitute for frozen tissue specimen staining in micrographic surgery. Lab Med. 2025. doi:10.1093/labmed/lmae099 PMID: 39673473
- [25]Wong E, Axibal E, Brown M. Mohs Micrographic Surgery. Facial Plast Surg Clin North Am. 2019. doi:10.1016/j.fsc.2018.08.002 PMID: 30420068
- [26]el-tal-2007-ihc-mohs
- [27]bricca-2004-ihc-frozen-section
About This Article
Author: Dr. Yehonatan Kaplan, M.D., Fellow ACMS
Last Medical Review:
Audience: Dermatologic Surgeons
Clinic: Kaplan Clinic · DermUnbound Research Program